Haemonetics Corporation, commonly known as HAE, is a leading global healthcare company. It was founded in 1971 and has its headquarters in Boston, Massachusetts. The company is a pioneer in the field of blood management solutions, with its products used in more than 50 countries all over the world.
Embodying a vision for advancing patient care and enhancing lives through innovative, medically necessary devices and services, HAE has established itself as a significant player in the medical device industry. The company provides a comprehensive suite of solutions that improve patient care, reduce healthcare costs, and save lives.
HAE operates through three segments: Hospital, Plasma, and Blood Center. Their products portfolio includes an extensive range of devices, information management software, and consulting services, all centered around blood. This product lineup ranges from transfusion medicine devices (to collect, separate, and safely process blood components) to surgical blood salvage systems and diagnostics tools.
The Hospital segment focuses on devices in the areas of surgical blood salvage, and hemostasis management. In contrast, the Plasma segment includes plasma collection devices and disposables. The Blood Center division designs and markets a range of equipment and related consumables used in the processing of blood and blood components.
One of HAE's innovations is TEG® 6s Hemostasis Analyzer System, a diagnostic instrument that provides rapid, comprehensive, and accurate identification of an individual’s hemostasis condition in a laboratory or point-of-care setting. It helps healthcare professionals quickly diagnose and treat critical bleeding conditions.
HAE’s commitment to innovation has seen the company invest significantly in research and development. The focus is on finding new solutions that address unmet needs in blood processing. The company's dedication to revolutionizing blood management has also seen it engage in several strategic acquisitions and alliances aimed at widening its reach and deepening its impact in parts of the healthcare space that it traditionally may not have had a significant presence.
However, It is important to note that the company, like any other in its field, has had to face numerous challenges. These range from regulatory hurdles to fluctuations in the global economy. Nonetheless, HAE’s ability to constantly adapt to a changing landscape has been instrumental in its success.
In conclusion, Haemonetics Corporation plays a critical role in the global healthcare industry. With over 50 years of existence and experience, the company continues to champion innovation and elevate standards in blood management. Despite the various challenges, HAE's commitment to its mission of compelling healthcare solutions ensures it continues to make a positive difference in healthcare globally.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Citigroup upgraded Haemonetics (HAE) to a "Buy" rating, raising its price target to $123 from $92.00, indicating optimism for the company's future performance in the healthcare sector. Despite the upgrade and a strong GF Score™ of 79/100, GuruFocus considers HAE modestly overvalued, trading 26.3% above its GF Value™ of $85.85. The company exhibits strong profitability and growth potential, but its momentum rank is lower, and its P/E ratio is significantly above its 5-year median.
Orchestra BioMed has received a $6.1 million milestone payment from Haemonetics following its acquisition of Vivasure. This payment is part of an existing agreement related to the acquisition. The news was published by MT Newswires.
Orchestra BioMed announced it received a $6.1 million milestone payment following the acquisition of Vivasure Medical by Haemonetics, bringing its total cash proceeds from the deal to approximately $11 million. The company remains eligible for up to an additional $10 million in future revenue earnouts. This payment further supports Orchestra BioMed's strategic initiatives and pivotal programs.
Haemonetics (HAE) is anticipated to report a year-over-year decline in earnings but higher revenues for the quarter ended June 2026. The Zacks Consensus Estimate for EPS is $1.07, down 2.7% from the prior year, with revenues expected to be $327.95 million, up 2%. The company's Earnings ESP is -4.67% and it holds a Zacks Rank of #4, making it difficult to confidently predict an earnings beat.
Robert W. Baird has raised its price target for Haemonetics (NYSE:HAE) to $119 from $96, maintaining an "outperform" rating, which suggests a potential upside of 9.74%. This positive forecast aligns with a broader "Moderate Buy" consensus among analysts, with Haemonetics also reporting strong quarterly earnings that surpassed expectations. Institutional ownership in the medical instruments supplier is significant, with 99.67% of shares held by such investors.